Last reviewed · How we verify
ibandronate [Bonviva/Boniva]
Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking the mevalonate pathway in osteoclasts.
Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking the mevalonate pathway in osteoclasts. Used for Osteoporosis in postmenopausal women, Bone metastases in breast cancer, Hypercalcemia of malignancy.
At a glance
| Generic name | ibandronate [Bonviva/Boniva] |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase (indirect); hydroxyapatite in bone (binding site) |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
Bisphosphonates like ibandronate are taken up by osteoclasts during bone resorption and inhibit farnesyl pyrophosphate synthase, disrupting the prenylation of small GTPases required for osteoclast function and survival. This leads to decreased bone turnover and increased bone mineral density, making it effective for conditions characterized by excessive bone loss.
Approved indications
- Osteoporosis in postmenopausal women
- Bone metastases in breast cancer
- Hypercalcemia of malignancy
Common side effects
- Musculoskeletal pain
- Gastrointestinal upset (nausea, dyspepsia)
- Headache
- Atypical femoral fracture (rare)
- Osteonecrosis of the jaw (rare)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ibandronate [Bonviva/Boniva] CI brief — competitive landscape report
- ibandronate [Bonviva/Boniva] updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI